Broncus (HKG:2216) plans to repurchase up to 52,719,807 of its shares on the market, representing around 10% of the total number of its issued shares, a Thursday Hong Kong bourse filing said.
The medical device company will make repurchases on the market from time to time until its next annual general meeting or until the share repurchase mandate is revoked.
The company will fund the repurchase with its existing cash reserves.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.